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Abstract
Background: For both in vitro and in vivo gene transfer applications, recombinant viral vectors have
almost always been used free in solution. Some site-specificity of the delivery of viral vectors can
be achieved by applying a solution containing viral particles specifically to the site of interest.
However, such site-specificity is seriously limited since viral vectors can diffuse freely in solution
after application.
Results: We have developed a novel strategy for in situ transduction of target cells on solid
surfaces by viral vectors. In this strategy, adenoviral vectors are attached stably to solid surfaces by
using the extremely tight interaction between (strept)avidin and biotin, while maintaining the
infectivity of the viral vectors. Target cells are cultured directly on such virus-coated solid surfaces,
resulting in the transduction of the cells, in situ, on the solid surface. When compared using an equal
number of viral particles present in each well (either immobilized or free), the efficiencies of such
in situ transduction on solid surfaces were equivalent to those seen with the adenoviral vectors
used free in solution. Since viral particles can be attached at desired locations on solid surfaces in
any sizes, shapes, and patterns, the ultimate spatial arrangements of transduced cells on solid
surfaces can be predetermined at the time of the preparation of the virus-coated solid surfaces.
Conclusions: We have devised a method of immobilizing adenoviral vectors, tightly and stably, on
solid surfaces, while maintaining their ability to infect cells. Such immobilized viral vectors can infect
target cells, in situ, on solid surfaces. This strategy should be very useful for the development of a
variety of both in vitro and in vivo applications, including the creation of cell-based expression arrays
for proteomics and drug discovery and highly site-specific delivery of transgenes for gene therapy
and tissue engineering.
Background
Recombinant viral vectors have become the primary
agents for both in vitro and in vivo gene transfer applica-
tions [1–4]. Viruses are powerful gene transfer agents,
since they have evolved specific, efficient machinery to de-
liver nucleic acids into cells. To our knowledge, viral vec-
tors have almost always been used free in solution. For in
vitro systems, a solution containing free viral vectors is ap-
plied to target cells. Similarly, free viral vectors in solution
are administered locally or systemically for in vivo gene
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transfer applications. Some site-specificity of the delivery
of viral vectors can be achieved by applying a solution
containing viral particles specifically to the site of interest
for both in vitro and in vivo settings. However, such site-
specificity is seriously limited since viral vectors can dif-
fuse freely in solution after application.
In this work, we have developed a novel strategy for virus-
mediated in situ transduction of target cells on solid sur-
faces using adenoviral vectors as gene transfer agents. In
this strategy, adenoviral particles are immobilized, tightly
and stably, on solid surfaces, while maintaining the natu-
ral properties of the viral vectors. We reasoned that such
immobilized viral vectors could infect cells only at the
contact site between the solid surface and cells. Thus, the
ultimate spatial arrangements of transduction sites on the
solid surface could be controlled and determined, at will,
by the strategic placement of viral vectors on the solid
surface.
Results
Virus-mediated in situ transduction of cells on solid 
surfaces
We have developed a novel strategy for virus-mediated in
situ transduction of target cells on solid surfaces using ad-
enoviral vectors as gene transfer agents. In this strategy,
adenoviral particles are immobilized, tightly and stably,
on solid surfaces (virus-coated solid surfaces), while
maintaining their natural properties, including infectivity.
We hypothesized that such viral vectors, immobilized on
a solid surface, could infect cells only at the contact site
between the solid surface and cells. This could allow the
spatial control and arrangements of transduction sites on
a solid surface, which can be determined by the strategic
placement of viral particles on the solid surface.
Infectivity of biotinylated adenoviral vectors immobilized 
on solid surfaces
The feasibility of this strategy was tested by using recom-
binant adenoviral vectors carrying a transducable lacZ (β-
galactosidase) gene (Ad5.CMV-LacZ) (Qbiogene, Mon-
treal, Canada). The extremely tight interaction between
the protein (strept)avidin and its ligand biotin (Kd ~ 10-14
M) [5–9] was chosen as a means of tethering viral particles
to the solid surface. We previously showed that biotin
moieties can be attached covalently to the outer surface of
adenoviral vectors without appreciable effect on their in-
fectivity under carefully controlled biotinylation condi-
tions [10,11]. Such biotinylated viral particles could be
attached, specifically and stably, to a solid surface on
which (strept)avidin is covalently immobilized (avidin-
or streptavidin-coated solid surface).
Biotinylation of Ad5.CMV-LacZ was performed by using
sulfo-NHS-LC-biotin (Pierce Chemical, Rockford, IL), a
biotin derivative containing an N-hydroxysuccinimidyl
ester (NHS) that reacts with primary amino groups.
Ad5.CMV-LacZ was treated at varying concentrations (0 –
100 µg/ml) of sulfo-NHS-LC-biotin on ice for 2 h in PBS
(pH 7.4), followed by the removal of non-virion-associat-
ed biotinylation reagent by ultrafiltration. The infectivities
of the resulting adenoviral vectors were analyzed by using
D-17 cells [canine osteosarcoma cell line; American Type
Culture Collection (ATCC), Manassas, VA] (highly per-
missive to adenoviral infection) [10] as targets. Little ef-
fect on viral infectivity was seen when the adenoviral
vectors were treated with sulfo-NHS-LC-biotin at concen-
trations up to approximately 40 µg/ml (data not shown).
This is in agreement with our earlier study [10].
These biotinylated adenoviral vectors were analyzed for
their ability to infect cells when immobilized on strepta-
vidin-coated solid surfaces. Ad5.CMV-LacZ was treated
with varying concentrations (0 – 30 µg/ml) of sulfo-NHS-
LC-biotin, and non-virion-associated biotinylation rea-
gent was removed by repeated ultrafiltration. The result-
ing biotinylated adenoviral vectors were incubated at
25°C for 2 h with gentle shaking in polystyrene wells, on
which streptavidin is covalently immobilized (well diam-
eter, 0.64 cm; Reacti-Bind Streptavidin Coated Polysty-
rene Strip Plates; Pierce Chemical) (5 × 106 viral particles
per well). The wells were washed to remove unbound viral
particles, and D-17 cells were placed directly in the wells
(8 × 103 cells per well) and cultured at 37°C for 48 h, fol-
lowed by the analysis of the expression of the lacZ gene
(Fig. 1). When Ad5.CMV-LacZ was treated with sulfo-
NHS-LC-biotin at a concentration of 0.6 µg/ml or lower,
almost no infection of D-17 cells was seen. In contrast,
substantial numbers of D-17 cells were transduced when
Ad5.CMV-LacZ was treated with 3 – 30 µg/ml sulfo-NHS-
LC-biotin. The maximum infectivity was seen with
Ad5.CMV-LacZ that had been treated with 15 µg/ml sulfo-
NHS-LC-biotin, where the infectivity was approximately
75% of that of unmodified Ad5.CMV-LacZ used free in so-
lution. These results suggest that, upon biotinylation of
the viral surface under controlled conditions, adenoviral
vectors can be immobilized on a solid surface by using the
(strept)avidin-biotin interaction, and that such immobi-
lized adenoviral vectors are capable of infecting cells, in
situ, on the solid surface.
Efficiency of immobilization of biotinylated adenoviral 
vectors
Biotinylated Ad5.CMV-LacZ, which had been treated with
15 µg/ml sulfo-NHS-LC-biotin followed by the removal
of unreacted biotinylated reagent, was used to determine
the immobilization efficiency of biotinylated adenoviral
vectors in streptavidin-coated wells. Known numbers of
biotinylated Ad5.CMV-LacZ particles were incubated in
streptavidin-coated wells for immobilization, and theBMC Biotechnology 2003, 3 http://www.biomedcentral.com/1472-6750/3/4
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number of viral particles remaining unbound in the solu-
tion was estimated from their infectivity on D-17 cells
(Fig. 2A). Despite the extremely tight streptavidin-biotin
interaction, only about 15 – 40% of viral particles were
bound to the surface of streptavidin-coated wells under
the conditions used where the number of viral particles
applied was considerably below saturation of the well sur-
face (estimated by both dimensional and biotin-binding
capacities of each well). This result is in contrast with our
previous study, which showed that greater than 95% of bi-
otinylated Ad5.CMV-LacZ, prepared under the same con-
ditions, can be readily captured on streptavidin-coated
microbeads [10]. Thus, the relatively low immobilization
efficiency of biotinylated Ad5.CMV-LacZ on the surface of
streptavidin-coated wells is not attributable to the absence
of accessible biotin moieties on the surfaces of a fraction
of viral particles or the presence of unreacted biotinyla-
tion reagent in the biotinylated Ad5.CMV-LacZ prepara-
tions. We hypothesized that the reduction of the
immobilization efficiency is caused by physical or fluidic
properties of viral vectors in wells, in which viral particles
may have a limited ability to migrate. To test this, a con-
stant number of fresh biotinylated Ad5.CMV-LacZ was ap-
plied to the same streptavidin-coated well repeatedly (2.5
× 106 viral particles per well per addition), with the re-
moval of unbound viral particles between the additions.
The efficiency of immobilization at each addition cycle
was determined from the number of viral particles re-
maining unbound in the solution (Fig. 2B). A relatively
constant number of viral particles was bound to the well
surface at each addition cycle of biotinylated Ad5.CMV-
LacZ. This means that the total number of viral particles
that were immobilized on the well surface increased
roughly proportionally to the number of the addition cy-
cle of biotinylated adenoviral particles. This result sug-
gests that the relatively low efficiency of immobilization
of biotinylated adenoviral vectors is caused by their fluidic
properties in wells, which allow only a fraction of viral
particles to reach the well surface and be captured by
streptavidin molecules on the well surface.
Infectivity of immobilized adenoviral vectors
The efficiency of in situ transduction by adenoviral vec-
tors, immobilized on streptavidin-coated wells, was inves-
tigated. Varying numbers of biotinylated Ad5.CMV-LacZ
(2.5 × 105 – 2.5 × 108 viral particles per well) were added
to streptavidin-coated wells (well diameter, 0.64 cm) for
immobilization, followed by the removal of unbound vi-
ral particles. D-17 cells were placed in these virus-coated
wells (8 × 102 cells per well) and cultured at 37°C for 48
h. Then, the infection of the cells was analyzed through
the expression of the lacZ gene. For comparison, the same
numbers of unmodified Ad5.CMV-LacZ were used free in
solution. The amount of infection increased with the in-
crease in the number of viral particles that were added to
the wells at the immobilization step (Fig. 3). However, the
amount of infection plateaued when 2.5 × 107viral parti-
cles were added to the well. Thus, when this number or
greater of viral particles was added to the well at the im-
mobilization step, all of the cells that had been applied
onto the virus-coated solid surface were transduced. When
unmodified Ad5.CMV-LacZ was used free in solution, the
saturation of infection was seen at 5 × 106 viral particles
per well. Up to this number of viral particles per well, used
for immobilization for biotinylated Ad5.CMV-LacZ or for
transduction by free Ad5.CMV-LacZ in solution,
immobilized adenoviral vectors showed lower infectivity
than free viral vectors. However, as shown in Fig. 2 above,
only about 15 – 40% of biotinylated Ad5.CMV-LacZ ap-
plied can actually be immobilized on streptavidin-coated
Figure 1
In situ transduction of target cells by adenoviral vec-
tors immobilized on a solid surface. Ad5.CMV-LacZ 
was treated with varying concentrations of sulfo-NHS-LC-
biotin, followed by the removal of non-virion-associated 
biotinylated reagent. The resulting viral vectors (5 × 106 viral 
particles per well) were incubated in streptavidin-coated 
wells (well diameter, 0.64 cm; Reacti-Bind Streptavidin 
Coated Polystyrene Wells) for 2 h at 25°C for immobiliza-
tion. After unbound viral particles were removed, D-17 cells 
(8 × 103 cells per well) were placed in the wells and cultured 
at 37°C for 48 h. Cells were fixed with glutaraldehyde and 
stained for the expression of the lacZ gene (● ). Biotinylated 
Ad5.CMV-LacZ (5 × 106 viral particles per well) was used 
free in solution as a control (❍ ). Data shown are representa-
tive of six independent experiments.
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Figure 2
Immobilization efficiency of biotinylated adenoviral vectors on streptavidin-coated wells. (A) Ad5.CMV-LacZ was 
treated with 15 µg/ml sulfo-NHS-LC-biotin, followed by the removal of non-virion-associated biotinylation reagent. Varying 
numbers of the resulting biotinylated adenoviral vectors (1 × 106 – 5 × 106 viral particles in 50 µl PBST per well) were incu-
bated in streptavidin-coated wells (well diameter, 0.64 cm; Reacti-Bind Streptavidin Coated Polystyrene Wells) for 2 h at 25°C 
for immobilization. The solution of each well, which contained unbound viral particles, was collected and analyzed for the infec-
tivity on D-17 cells (❍ ). The same numbers of biotinylated Ad5.CMV-LacZ without application to streptavidin-coated wells 
were also analyzed for the infectivity on D-17 cells (● ). The infectivity of immobilized viral particles was calculated by subtrac-
tion of the infectivity of unbound viral particles from the total infectivity of Ad5.CMV-LacZ applied to each well. The percent-
age of immobilized viral particles in the total is shown at the top. Each data point shown is the average + SD (n = 3). (B) 
Biotinylated Ad5.CMV-LacZ, prepared as above, was incubated in streptavidin-coated wells (2.5 × 106 viral particles per well) 
for 30 min at 25°C. The solution of each well was collected, and the wells were washed three times with PBST. Then, the same 
number of fresh biotinylated Ad5.CMV-LacZ was incubated in the same manner as above. These steps were repeated several 
more times. The solution in the well, which contained unbound viral particles, was collected after each addition cycle and 
titrated on D-17 cells (open bars). The Control bar shows the total infectivity of biotinylated Ad5.CMV-LacZ that was applied 
to wells at each addition cycle. The infectivity of immobilized viral particles (solid bars) was calculated by subtraction of the 
infectivity of unbound viral particles from the total infectivity of Ad5.CMV-LacZ applied at each addition cycle. The percentage 
of immobilized viral particles in the total at each addition cycle is shown at the top. Each data point shown is the average ± SD 
(n = 3).
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wells. Thus, if the infectivity is compared using the actual
number of viral particles present in each well, Ad5.CMV-
LacZ, immobilized on streptavidin-coated wells, may pos-
sess an infectivity equivalent to that of free adenoviral
vectors.
We next investigated how the infection of target cells by
immobilized adenoviral vectors on the solid surface is af-
fected by the natural permissivity of target cells for adeno-
viral infection, determined by using free adenoviral
vectors in solution. Varying numbers of biotinylated
Ad5.CMV-LacZ, prepared by treatment with 15 µg/ml sul-
fo-NHS-LC-biotin, were applied to streptavidin-coated
wells (well diameter, 0.64 cm) for immobilization,
followed by the removal of unbound viral particles. Target
cells (8 × 103 per well) were cultured directly on the virus-
coated wells at 37°C for 48 h, followed by the detection
of the expression of the lacZ gene. Unmodified Ad5.CMV-
LacZ were used free in solution for comparison. Two cell
lines were used as targets. One cell line is D-17, which is
highly permissive to adenoviral infection when viral vec-
tors are used free in solution [10]. The other cell line is C6
(rat glioma cells), which is less permissive to adenoviral
infection [10]. For D-17 cells, the amount of infection in-
creased steeply when the number of viral particles added
to each well increased from 2.5 × 105 to 2.5 × 10 6 (Fig.
4A) for both immobilized and free adenoviral vectors, al-
though free Ad5.CMV-LacZ showed higher infectivity
than immobilized adenoviral vectors. This result is con-
sistent with that shown in Fig. 3. For C6 cells, no appreci-
able infection was seen with free Ad5.CMV-LacZ even
when 2.5 × 107 viral particles were used per well (Fig. 4B).
In contrast, when C6 cells were cultured directly on
streptavidin-coated wells, on which Ad5.CMV-LacZ had
been immobilized, considerable amounts of infection
were seen when 2.5 × 106 viral particles per well and great-
er were added to wells at the immobilization step. This re-
sult suggests the possibility that adenoviral vectors, which
are immobilized on a solid surface, can infect target cells
that are otherwise poorly permissive to infection by free
adenoviral vectors. Provided that this notion is correct,
this enhanced infectivity of immobilized adenoviral vec-
tors for poorly permissive target cells might be derived
from the fact that target cells are forced to make direct
contact with adenoviral vectors on the solid surface, rais-
ing the local concentration of viral particles on the cell
surface. Thus, unlike the infection of cells by free adenovi-
ral vectors, the collision of viral particles with the cell sur-
face and the amount of the primary receptor for
adenoviral vectors (coxsackie-adenovirus receptor; CAR)
on target cells might not serve as the primary determi-
nants for the permissivity of the cells. However, this en-
hanced infectivity of immobilized adenoviral vectors was
not seen with all the cell lines tested that are poorly per-
missive to adenoviral infection. For example, the
infectivity of immobilized Ad5.CMV-LacZ was analyzed
for two human colon adenocarcinoma cell lines, HT-29
(ATCC) and COLO205 (ATCC), which are highly resistant
to adenoviral infection [12]. HT-29 expresses only a small
amount of CAR on the cell surface. Adenoviral particles
can be taken up relatively efficiently by this cell line, but
this does not result in transduction of cells. Thus, the ex-
pression of transgenes is extremely poor [12]. The expres-
sion of CAR on the surface of COLO205 cells is even lower
than HT-29 cells, and such CAR expression can be seen on
only about 50% of COLO205 cells. Similar to HT-29 cells,
the transduction efficiency of adenoviral vectors for
COLO205 is extremely poor [12]. The very low transduc-
tion efficiency of COLO205 by adenoviral vectors, used
free in solution, was confirmed in our previous study [10].
When up to 2.5 × 107 viral particles were added to each
well at the immobilization step (or for transduction by
free Ad5.CMV-LacZ), the infectivity of immobilized
Ad5.CMV-LacZ was only slightly higher than free
Figure 3
Effect of the amount of adenoviral vectors on in situ 
transduction of target cells on a solid surface. 
Ad5.CMV-LacZ was treated with 15 µg/ml sulfo-NHS-LC-
biotin, followed by the removal of non-virion-associated 
biotinylation reagent. Varying numbers of the resulting bioti-
nylated adenoviral vectors (2.5 × 105 – 2.5 × 108 viral parti-
cles per well) were added to streptavidin-coated wells (well 
diameter, 0.64 cm; Reacti-Bind Streptavidin Coated Polysty-
rene Wells) for immobilization, followed by the removal of 
unbound viral particles. Then, D-17 cells (8 × 102 cells per 
well) were placed on the wells and cultured at 37°C for 48 h. 
Cells were fixed with glutaraldehyde and stained for the 
expression of the lacZ gene (● ). Unmodified Ad5.CMV-LacZ 
was used free in solution as a control (❍ ). Data shown are 
representative of five independent experiments.
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Figure 4
Effect of the natural permissivity of target cells for adenoviral infection on in situ transduction of the cells by 
adenoviral vectors immobilized on a solid surface. A, D-17 cells (canine osteosarcoma cell line that is highly permissive 
to adenoviral infection); B, C6 cells (rat glioma cell line that is poorly permissive to adenoviral infection). Ad5.CMV-LacZ was 
treated with 15 µg/ml sulfo-NHS-LC-biotin, followed by the removal of non-virion-associated biotinylation reagent. Varying 
numbers of the resulting biotinylated adenoviral vectors were added to streptavidin-coated wells (well diameter, 0.64 cm; 
Reacti-Bind Streptavidin Coated Polystyrene Wells) for immobilization, followed by the removal of unbound viral particles. 
Target cells (8 × 103 cells per well) were placed on the wells and cultured at 37°C for 48 h. Cells were fixed with glutaralde-
hyde and stained for the expression of the lacZ gene (● ). Unmodified Ad5.CMV-LacZ was used free in solution as a control 
(❍ ). Data shown in A and B are representative of three and four, respectively, independent experiments.
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Ad5.CMV-LacZ in solution (data not shown). This might
imply that the binding of viral particles to CAR is still re-
quired for the in situ infection of target cells on solid sur-
faces by immobilized adenoviral vectors.
Adenoviral vector spots on solid surfaces
Successful in situ infection of target cells by adenoviral vec-
tors on a solid surface, shown above, suggests that this
technology could be used to control, spatially, the loca-
tion of gene transduction on a solid surface by strategic
placement of viral vectors. There are several possible ways
of immobilizing viral vectors at predetermined locations
on the solid surface by using the (strept)avidin-biotin in-
teraction. We used one such method to fabricate solid sur-
faces with adenoviral vectors immobilized as discrete
spots with predetermined sizes. In this method, biotin
moieties were initially attached covalently to discrete re-
gions on a solid surface. To the biotin moieties on the sol-
id surface, biotinylated adenoviral vectors were attached
by using avidin as a molecular bridge between the biotin
moieties on the solid surface and the viral surface. Cell
culture plates, which are coated with poly-D-lysine (well
diameter, 3.5 cm; Biocoat Poly-D-Lysine Cellware 6-Well
Plates; Becton Dickinson Labware, Bedford, MA), were
used as the solid surface. Sulfo-NHS-LC-biotin was used
to attach biotin moieties, covalently, to the primary ami-
no groups of poly-D-lysine on the solid surface. During
the biotinylation reaction, plastic rings (inner diameter,
1.4 cm) and agarose were used to delimit the regions of bi-
otinylation on the solid surface and to protect the remain-
ing areas from biotinylation, respectively. After unreacted
biotinylation reagent was removed, excess Neutralite
avidin (a deglycosylated, neutralized form of avidin;
Southern Biotechnology Associates, Alabama, AL) was
added, which should bind to biotin moieties on the solid
surface. After the removal of unbound Neutralite avidin,
Ad5.CMV-LacZ, which had been biotinylated by treat-
ment with 15 µg/ml sulfo-NHS-LC-biotin as above, was
applied to the wells and allowed to bind to unoccupied
biotin-binding sites of Neutralite avidin that had been
bound to biotin moieties on the solid surface. D-17 cells
were applied to the entire wells (2.5 × 105 cells per well)
and cultured at 37°C for 48 h, followed by the detection
of the expression of the lacZ gene (Fig. 5). Specific trans-
duction of target cells is seen only at the locations (spots)
where biotin moieties were initially attached. This dem-
onstrates regio-specific in situ transduction of target cells
by adenoviral vectors at predetermined locations. Very
limited numbers of infected cells were present outside the
biotinylation areas, indicating that biotinylated
Ad5.CMV-LacZ was bound specifically to biotin moieties
on the well surface via Neutralite avidin. This result re-
veals that the ultimate spatial arrangements of transduced
cells on a solid surface can be controlled and predeter-
mined at the time of the fabrication of the solid surface,
during which time viral vectors can be attached to desired
locations in any shapes, patterns, and sizes.
Discussion
We previously reported a strategy similar to the one de-
scribed in this study. In this strategy, biotinylated adeno-
viral vectors are immobilized on the surfaces of
streptavidin-coated microbeads with diameters up to a
few micrometers [10]. For such adenovirus-microbead
conjugates, great enhancement in transduction efficiency
was seen with several different cell lines, including
COLO205, the infection efficiency of which was not nota-
bly enhanced by adenoviral vectors immobilized on
streptavidin-coated wells in the present study. The prima-
ry difference between the two strategies is derived from
the size of solid surfaces (streptavidin-coated wells and
streptavidin-coated microbeads) relative to target cells.
The sizes of adenovirus-microbead conjugates are smaller
than those of target cells. Thus, the entire adenovirus-mi-
crobead conjugates can be taken up by cells. Such inter-
nalization events appear to contribute substantially to the
infectivity enhancement by virus-microbead conjugates.
In contrast, the dissociation of viral particles from the sol-
id surface must occur for adenoviral vectors, which are in-
itially immobilized on streptavidin-coated wells, to be
taken up by target cells. This may be one possible explana-
tion of why infectivity enhancement was seen with aden-
ovirus-microbead conjugates and was not with adenoviral
vectors immobilized on streptavidin-coated wells, except
for one cell line (C6).
Virus-coated solid surfaces should offer a variety of both
in vitro and in vivo applications. One such in vitro applica-
tion would be the creation of virus arrays for expression
and functional analysis of genes [13,14]. A recombinant
viral vector library, each clone of which carries a different
gene, could be immobilized in an ordered manner as
discrete spots on a solid surface. Onto the resulting virus
array, target cells are applied and cultured. This should
result in the expression of encoded genes in target cells in
an array format, in which each encoded gene should be
expressed in a discrete cell spot while maintaining the
original location of the viral vector spot in the virus array.
Thus, expression and functional analysis of many differ-
ent genes can potentially be performed with a single virus
array for a given target cell line. The use of viral vectors
should offer enhanced efficiencies and versatility for the
expression of cloned genes in various cell types than ap-
proaches using expression plasmids that are printed on
solid surfaces [15,16]. This might be particularly true to
primary cells, which often show poor expression of en-
coded genes when plasmid-based expression vectors are
used. The availability of such viral vector libraries, partic-
ularly those based on adenoviral vectors [17,18], should
facilitate the realization of such applications. Virus-coatedBMC Biotechnology 2003, 3 http://www.biomedcentral.com/1472-6750/3/4
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solid surfaces could also be used for in vitro tissue engi-
neering applications, for which the shapes and sizes of ar-
eas/regions of genetically engineered cells can be
predetermined two-dimensionally by strategic placement
and patterning of viral vectors on solid surfaces, as exem-
plified in Fig. 5. Such precise control of the shapes and siz-
es of areas/regions of genetically engineered cells would
be very difficult to achieve with free viral vectors, which
can diffuse freely in solution.
Virus-coated solid surfaces could also be used in vivo for
highly site-specific delivery of viral particles to target tis-
sues or cells through the direct application of virus-coated
solid surfaces to target sites. The delivery of viral vectors in
a solid-surface-associated form should eliminate the mi-
gration of viral particles from the administration site,
minimizing uncontrolled transduction of non-target tis-
sues. For example, a virus-coated solid surface, the size of
which has been adjusted to the intended transduction site,
could be transplanted into a target tissue, allowing the
specific transduction of the target site by immobilized vi-
ral vectors with minimal infection of surrounding tissues.
As proposed for in vitro applications described above, the
primary advantage for such in vivo gene transfer applica-
tions would be that the shapes and sizes of areas/regions
of transduction sites can be predetermined by strategic
placement and patterning of viral vectors on solid
surfaces.
Conclusions
We have devised a method of immobilizing adenoviral
vectors, tightly and stably, on solid surfaces using the
(strept)avidin-biotin interaction, while maintaining their
ability to infect cells. Such immobilized viral vectors can
infect target cells, in situ, on solid surfaces with efficiencies
equivalent to the same viral vectors used free in solution
for the cell lines tested. For one cell line (C6), the infec-
tion efficiency by immobilized viral vectors was greater
than the same viral vectors used free in solution, which
showed a limited ability to infect the target cells. This
strategy should be very useful for the development of a va-
riety of both in vitro and in vivo applications, including the
creation of cell-based expression arrays for proteomics
and drug discovery and highly site-specific delivery of
transgenes for gene therapy and tissue engineering.
Methods
Adenoviral vectors
The recombinant adenoviral vectors used are Ad5.CMV-
LacZ (Qbiogene), which is derived from adenovirus sero-
type 5 with the deletion of the viral E1A, E1B, and E3
genes. Ad5.CMV-LacZ carries the bacterial lacZ (β-galac-
tosidase) gene under the control of the human cytomega-
lovirus (CMV) immediate-early promoter with the human
β-globin polyadenylation signal sequence. This viral
Figure 5
Regio-specific transduction of target cells on a solid 
surface by immobilized adenoviral vectors. Six-well 
cell culture plates, coated with poly-D-lysine (well diameter, 
3.5 cm; Biocoat Poly-D-Lysine Cellware 6-Well Plates), were 
used as the solid surface. First, spots of biotin moieties on 
the wells were created by using sulfo-NHS-LC-biotin. Plastic 
rings (inner diameter, 1.4 cm) were used to specify biotinyla-
tion areas, and the remaining area of the wells was covered 
with a layer of 2% agarose. These spot areas within plastic 
rings were treated with 1 mg/ml sulfo-NHS-LC-biotin in PBS 
(pH 7.4) (50 µl per spot) for 2 h at 4°C, followed by the 
remove of unreacted biotinylation reagent. Neutralite avidin 
(25 µg in 50 µl PBST per spot) was added to the spot areas 
within the plastic rings and allowed to bind to biotin moieties 
of the well surface. Unbound Neutralite avidin was removed, 
and biotinylated Ad5.CMV-LacZ (1 × 107 viral particles per 
spot), prepared by treatment with 15 µg/ml sulfo-NHS-LC-
biotin, was incubated in the spot areas within plastic rings at 
25°C for 2 h, followed by the removal of unbound viral parti-
cles. The plastic rings and agarose were removed from the 
wells, which were then washed with PBS. D-17 cells (2.5 × 
105 per well) were applied to the entirety of the wells, cul-
tured at 37°C for 48 h, and stained for the expression of the 
lacZ gene.BMC Biotechnology 2003, 3 http://www.biomedcentral.com/1472-6750/3/4
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vector had been purified by two rounds of CsCl gradient
centrifugation.
Target cells
The following two cell lines were used as targets for aden-
oviral infection: D-17 (canine osteosarcoma cells) and C6
(rat glioma cells), both of which were obtained from
ATCC. These cell lines were grown at 37°C in a humidi-
fied atmosphere containing 5% CO2. D-17 cells were
maintained in Dulbecco's modified Eagles medium
(DMEM; BioWhittaker) supplemented with 6% fetal bo-
vine serum (FBS; BioWhittaker), and C6 cells were in
DMEM supplemented with 10% FBS.
Biotinylation of adenoviral vectors with sulfo-NHS-LC-bi-
otin
Sulfo-NHS-LC-biotin (Pierce Chemical) was dissolved in
dimethylformamide at a concentration of 3 mg/ml and
added to Ad5.CMV-LacZ [1.0 × 109 viral particles in 100
µl PBS (pH 7.4)] to various final concentrations (0 – 100
µg/ml). The reaction mixtures were incubated on ice in
the dark for 2 h, and the biotinylation reaction was termi-
nated by the addition of 100 µl of 9 mM glycine in PBS
(pH 7.4). The viral particles were subjected to three
rounds of ultrafiltration with ZM-500 centrifugal filtra-
tion units (molecular mass cut-off, 500 kDa; Millipore)
using PBS (pH 7.4) containing 0.05% Tween 20 (PBST) as
a diluent to remove non-virion-associated biotinylation
reagent. Finally, the viral particles were suspended in 100
µl of fresh PBST at a concentration of 1 × 1010  viral
particles/ml.
For the infectivity analysis of biotinylated Ad5.CMV-LacZ,
dilutions of biotinylated viral vectors were placed over
monolayers of D-17 target cells on a 96-well cell culture
plate (8 × 103 cells per well), followed by the incubation
of cells at 37°C for 48 h. Then, cells were fixed with 0.5%
glutaraldehyde and stained for β-galactosidase (LacZ) ac-
tivity using 5-bromo-4-chloro-3-indoyl-β-D-galactopyro-
noside (X-Gal) as the substrate. The numbers of infected,
lacZ-expressing cells for 10–15 randomly chosen micro-
scopic fields (3.75 mm2) in each well were counted and
used to assess the total number of infected cells in each
well.
Preparation of wells coated with adenoviral vectors
Biotinylated Ad5.CMV-LacZ, prepared by treatment with
15 µg/ml sulfo-NHS-LC-biotin as above, was diluted in
PBST and incubated for immobilization in streptavidin-
coated wells (well diameter, 0.64 cm; Reacti-Bind
Streptavidin Coated Polystyrene Wells, Pierce Chemical)
(50 µl per well) for 2 h at 25°C with shaking on a rotary
shaker at 150 rpm. The solution of each well, which con-
tained unbound Ad5.CMV-LacZ, was collected and ana-
lyzed for infectivity on D-17 cells as above to estimate the
number of unbound viral particles. The wells were washed
with PBST and then with PBS (pH 7.4) without Tween 20.
Onto the wells coated with biotinylated Ad5.CMV-LacZ,
target cells were placed and cultured at 37°C for 48 h.
Cells were fixed with glutaraldehyde and stained for the
expression of the lacZ gene as described above. For control
experiments, a solution containing free, unmodified
Ad5.CMV-LacZ (50 µl per well) was applied to target cells
grown on streptavidin-coated wells.
Repeated application of biotinylated adenoviral vectors to 
wells
Biotinylated Ad5.CMV-LacZ, prepared by treatment with
15 µg/ml sulfo-NHS-LC-biotin as above, was diluted in
PBST and added to streptavidin-coated wells (2.5 × 106 vi-
ral particles in 50 µl PBST per well) and incubated with
shaking on a rotary shaker at 150 nm at 25°C for 30 min.
The solution in each well, which contained unbound viral
particles, was collected, and the wells were washed three
times with PBST. Then, the same number of fresh bioti-
nylated Ad5.CMV-LacZ was added to the well and incu-
bated in the same manner, followed by the collection of
unbound viral particles and washing of the wells. These
steps were repeated several more times. The unbound vi-
ral particle fraction, collected after each addition cycle,
was subjected to infectivity analysis on D-17 cells to esti-
mate the number of unbound Ad5.CMV-LacZ.
Preparation of adenoviral vector spots on solid surfaces
Six-well cell culture plates, coated with poly-D-lysine
(well diameter, 3.5 cm; Biocoat Poly-D-Lysine Cellware 6-
Well Plates, Becton Dickinson Labware), were used as the
solid surface. First, spots of biotin moieties on the wells
were created by using sulfo-NHS-LC-biotin. Plastic rings
(inner diameter, 1.4 cm) were used to specify the bioti-
nylation areas, and the remaining area of the wells was
covered with a layer of 2% agarose in PBS. These spot are-
as within plastic rings were treated with 1 mg/ml sulfo-
NHS-LC-biotin in PBS (pH 7.4) (50 µl per spot) for 2 h at
4°C and then washed with PBST to remove unreacted bi-
otinylation reagent. Neutralite avidin (Southern Biotech-
nology Associates) (25 µg in 50 µl PBST per spot) was
added to the spot areas within plastic rings, which had
been treated with sulfo-NHS-LC-biotin, and allowed to
bind to biotin moieties on the well surface. Unbound
Neutralite avidin was removed by washing the wells with
PBST. Biotinylated Ad5.CMV-LacZ (1 × 107 viral particles
per spot), prepared by treatment with 15 µg/ml sulfo-
NHS-LC-biotin as above, were incubated in the spot areas
within plastic rings at 25°C for 2 h, followed by washing
the wells with PBST to remove unbound viral particles.
The plastic rings and agarose were removed from the
wells, and the entire wells were washed with PBS. D-17
cells (2.5 × 105 per well) were applied to the entire wells
and cultured at 37°C for 48 h. Cells were fixed withPublish with BioMed Central    and   every 
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glutaraldehyde and stained for the expression of the lacZ
gene as described above.
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